Trough levels of anti-TNF agents in inflammatory bowel disease

• Research type

  Research Study

• Full title

  Utilising drug levels and anti-drug antibodies to predict response to treatment in patients with Inflammatory Bowel Disease

• IRAS ID

  88234

• Contact name

  Sreedhar Subramanian

• Sponsor organisation

  Royal Liverpool University Hospital

• Eudract number

  2011-006084-22

• Research summary

  Inflammatory bowel disease (IBD) is a chronic condition which affects the gastrointestinal tract and typically causes diarrhoea and abdominal pain. IBD mainly affects young people and causes considerable morbidity and some mortality in the western world. IBD is often treated with medications such as Azathioprine and newer biological agents known as the anti-tumour necrosis factor (TNF) antibodies (infliximab or adalimumab). Unfortunately, not all patients respond to biological agents and some lose response with time. It appears that the level of drug in the blood (trough level) before the next dose and antibodies against the drug (anti-drug antibodies) may play a role in response to the drug. Our study aims to investigate these factors in detail.

• REC name

  North West - Liverpool Central Research Ethics Committee

• REC reference

  12/NW/0274

• Date of REC Opinion

  30 Apr 2012

• REC opinion

  Favourable Opinion